Department of Urology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Gyeonggi-do, Republic of Korea.
Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.
Sci Rep. 2024 Feb 12;14(1):3497. doi: 10.1038/s41598-024-54232-4.
We compared the progression patterns after radical nephroureterectomy (RNU) and elective distal ureterectomy (DU) in patients with urothelial carcinoma of the distal ureter. Between Jan 2011 and Dec 2020, 127 patients who underwent RNU and 46 who underwent elective DU for distal ureteral cancer were enrolled in this study. The patterns of progression and upper tract recurrence were compared between the two groups. Progression was defined as a local recurrence and/or distant metastasis after surgery. Upper tract recurrence and subsequent treatment in patients with DU were analyzed. Progression occurred in 35 (27.6%) and 10 (21.7%) patients in the RNU and DU groups, respectively. The progression pattern was not significantly different (p = 0.441), and the most common progression site was the lymph nodes in both groups. Multivariate logistic regression analysis revealed that pT2 stage, concomitant lymphovascular invasion, and nodal stage were significant predictors of disease progression. Upper tract recurrence was observed in nine (19.6%) patients with DU, and six (66.7%) patients had a prior history of bladder tumor. All patients with upper tract recurrence after DU were managed with salvage RNU. Elective DU with or without salvage treatment was not a risk factor for disease progression (p = 0.736), overall survival (p = 0.457), cancer-specific survival (p = 0.169), or intravesical recurrence-free survival (p = 0.921). In terms of progression patterns and oncological outcomes, there was no difference between patients who underwent RNU and elective DU with/without salvage treatment. Elective DU should be considered as a therapeutic option for distal ureter tumor.
我们比较了根治性肾输尿管切除术(RNU)和选择性远端输尿管切除术(DU)治疗输尿管下段尿路上皮癌患者的进展模式。2011 年 1 月至 2020 年 12 月,我们共纳入了 127 例行 RNU 和 46 例行选择性 DU 治疗输尿管下段癌的患者。比较了两组患者的进展模式和上尿路复发情况。进展定义为手术后局部复发和/或远处转移。分析了 DU 患者的上尿路复发和后续治疗情况。RNU 和 DU 组分别有 35(27.6%)例和 10(21.7%)例患者发生进展。两组的进展模式无显著差异(p=0.441),且最常见的进展部位均为淋巴结。多因素 logistic 回归分析显示,T2 期、合并脉管侵犯和淋巴结分期是疾病进展的显著预测因素。9 例(19.6%)DU 患者出现上尿路复发,6 例(66.7%)患者有膀胱肿瘤病史。所有 DU 后上尿路复发患者均行挽救性 RNU 治疗。选择性 DU 联合或不联合挽救治疗不是疾病进展(p=0.736)、总生存(p=0.457)、癌症特异性生存(p=0.169)或膀胱内无复发生存(p=0.921)的危险因素。就进展模式和肿瘤学结局而言,行 RNU 与选择性 DU 联合或不联合挽救治疗的患者之间无差异。选择性 DU 可作为治疗输尿管下段肿瘤的一种治疗选择。